Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 3/20 | 0.34 |
| ▸ | CHRM4 | P08173 | 3/20 | 0.34 |
| ▸ | CHRM5 | P08912 | 3/20 | 0.34 |
| ▸ | CHRM1 | P11229 | 3/20 | 0.34 |
| ▸ | CHRM3 | P20309 | 3/20 | 0.34 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.31 |
| ▸ | OPRL1 | P41146 | 2/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4670206 | 0.81 | PKM (0.39) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL4681145 | 0.79 | HTT (0.41) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL4681766 | 0.77 | HTT (0.43) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL2991774 | 0.77 | HTT (0.43) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL17001874 | 0.74 | CHRM2 (0.36) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL18444558 | 0.74 | PLG (0.34) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL17001769 | 0.74 | PLG (0.34) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL17001872 | 0.74 | CHRM2 (0.36) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL17001786 | 0.74 | PLG (0.34) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL5899795 | 0.70 | CHRM2 (0.36) | CHRM2CHRM4CHRM5CHRM1CHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1605756-A4 | PRODUCTION OF 5-METHYL-N-ARYL-2-PYRROLIDONE AND 5-METHYL-N-ALKYL-2-PYRROLIDONE BY REDUCTIVE AMINATION OF LEVULINIC ACID ESTERS WITH ARYL AND ALKYL AMINES | DU PONT (US) | 2008-08-13 | — | — | EP | disclosed |
| US-7129362-B2 | Production of 5-methyl-N-aryl-2-pyrrolidone and 5-methyl-N-alkyl-2-pyrrolidone by reductive of levulinic acid esters with aryl and alkyl amines | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 2006-10-31 | — | — | US | disclosed |
| CN-1764379-A | Production of 5-methyl-N-aryl-2-pyrrolidone and 5-methyl-N-alkyl-2-pyrrolidone | DU PONT (US) | 2006-04-26 | — | — | CN | disclosed |
| EP-1605756-A2 | PRODUCTION OF 5-METHYL-N-ARYL-2-PYRROLIDONE AND 5-METHYL-N-ALKYL-2-PYRROLIDONE BY REDUCTIVE AMINATION OF LEVULINIC ACID ESTERS WITH ARYL AND ALKYL AMINES | E.I. DUPONT DE NEMOURS AND COMPANY (US) | 2005-12-21 | — | — | EP | disclosed |
| US-20050137406-A1 | Production of 5-methyl-N-aryl-2-pyrrolidone and 5-methyl-N-alkyl-2-pyrrolidone by reductive of levulinic acid esters with aryl and alkyl amines | E. I. DU PONT DE NEMOURS AND COMPANY | 2005-06-23 | — | — | US | disclosed |
| US-20050038265-A1 | Production of 5-methyl-N-aryl-2-pyrrolidone and 5-methyl-N-alkyl-2-pyrrolidone by reductive amination of levulinic acid esters with aryl and alkyl amines | MANZER LEO ERNEST (US) | 2005-02-17 | — | — | US | disclosed |
| US-20050033062-A1 | Production of 5-methyl-N-aryl-2-pyrrolidone and 5-methyl-N-alkyl-2-pyrrolidone by reductive amination of levulinic acid esters with aryl and alkyl amines | MANZER LEO ERNEST (US) | 2005-02-10 | — | — | US | disclosed |
| US-20050033063-A1 | Production of 5-methyl-N-aryl-2-pyrrolidone and 5-methyl-N-alkyl-2-pyrrolidone by reductive amination of levulinic acid esters with aryl and alkyl amines | MANZER LEO ERNEST (US) | 2005-02-10 | — | — | US | disclosed |
| WO-2004085348-A2 | PRODUCTION OF 5-METHYL-N-ARYL-2-PYRROLIDONE AND 5-METHYL-N-ALKYL-2-PYRROLIDONE | E.I. DUPONT DE NEMOURS AND COMPANY (US) | 2004-10-07 | — | — | WO | disclosed |
| US-20040192938-A1 | Production of 5-mehyl-N-aryl-2-pyrrolidone and 5-methyl-N-alkyl-2-pyrrolidone by reductive of levulinic acid esters with aryl and alkyl amines | E. I. DU PONT DE NEMOURS AND COMPANY | 2004-09-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050033063-A1 | Production of 5-methyl-N-aryl-2-pyrrolidone and 5-methyl-N-alkyl-2-pyrrolidone by reductive amination of levulinic acid esters with aryl and alkyl amines | ALDH18A1, PNPO, ABAT | CHRM2 1774/4885CHRM4 2162/4885CHRM5 580/4885 |
| US-20050137406-A1 | Production of 5-methyl-N-aryl-2-pyrrolidone and 5-methyl-N-alkyl-2-pyrrolidone by reductive of levulinic acid esters with aryl and alkyl amines | ALDH18A1, PNPO, ABAT | CHRM2 1906/4885CHRM4 2310/4885CHRM5 674/4885 |
| US-20040192938-A1 | Production of 5-mehyl-N-aryl-2-pyrrolidone and 5-methyl-N-alkyl-2-pyrrolidone by reductive of levulinic acid esters with aryl and alkyl amines | PAH, ALDH18A1, PNPO | CHRM2 1879/4885CHRM4 1976/4885CHRM5 449/4885 |
| US-20050038265-A1 | Production of 5-methyl-N-aryl-2-pyrrolidone and 5-methyl-N-alkyl-2-pyrrolidone by reductive amination of levulinic acid esters with aryl and alkyl amines | ALDH18A1, PNPO, ABAT | CHRM2 1774/4885CHRM4 2162/4885CHRM5 580/4885 |
| US-20050033062-A1 | Production of 5-methyl-N-aryl-2-pyrrolidone and 5-methyl-N-alkyl-2-pyrrolidone by reductive amination of levulinic acid esters with aryl and alkyl amines | ALDH18A1, PNPO, ABAT | CHRM2 1774/4885CHRM4 2162/4885CHRM5 580/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.